About this Journal Submit a Manuscript Table of Contents
Neurology Research International
Volume 2012 (2012), Article ID 853030, 2 pages
http://dx.doi.org/10.1155/2012/853030
Erratum

Erratum to “Progress in Therapy Development for Amyotrophic Lateral Sclerosis”

1Department of Pathology, University of Toledo Medical Center, 3000 Arlington Avenue, Toledo, OH 43614, USA
2Department of Neurosciences, University of Toledo Medical Center, 3000 Arlington Avenue, Toledo, OH 43614, USA

Received 15 August 2012; Accepted 16 August 2012

Copyright © 2012 Kalina Venkova-Hristova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Please consider the following changes in Table 1.

tab1
Table 1: Mendelian and non-Mendelian loci known to cause FALS or confer risk for SALS. Information in this table reproduces content in Tables  7 and 8 from Lill and Bertram, 2011 ([2], and databases therein). Polymorphisms in the VEGF promoter that were originally associated with increased ALS risk have not been confirmed in subsequent studies but may act as modifiers of disease onset or progression in subsets of ALS cases [58].